Zinbryta risks outweigh benefits, European report
Zinbryta risks outweigh benefits, European report
Multiple sclerosis treatment Zinbryta was withdrawn in March and now a review by the European Medicines Agency has found its risks outweigh its benefits.
The review confirms the drug’s association with the risk of developing severe and potentially fatal immune reactions in the brain, liver and other organs. It was carried out by to the European Medicines Agency‘s (EMA)’s Pharmacovigilance Risk…
View On WordPress


















